medwireNews: Sotagliflozin treatment may reduce repeat hospitalizations and increase the amount of time people with type 2 diabetes and heart failure are alive and not in hospital, shows further analysis of SOLOIST-WHF.
As previously reported, sotagliflozin treatment versus placebo resulted in a significant 33% reduction in the primary outcome of cardiovascular death, heart failure hospitalization, and urgent visits for heart failure among people with type 2 diabetes who also had heart failure.
The latest results “provide additional patient-centered metrics to capture the totality of disease burden and have important implications for patient quality of life and healthcare costs,” Michael Szarek (University of Colorado, Aurora, USA) told attendees of the virtual American College of Cardiology 70th Annual Scientific Session.
In this latest analysis, the team looked at broader measures of hospitalization, as an important component of overall disease burden.
Szarek reported that although a similar proportion of each treatment group was hospitalized at least once during the median 9-month follow-up, there was a significant difference in the proportions hospitalized more than once, at 16.3% of the 608 participants randomly assigned to the sotagliflozin group and 22.1% of the 614 participants given placebo.
The rate of total hospitalizations was significantly lower in the sotagliflozin than the placebo group, at 97.6 versus 126.6 per 100 patient–years. This was primarily due to a significantly lower rate of total hospitalizations for heart failure, at a corresponding 33.4 versus 51.4 per 100 patient–years. There was also a trend toward a reduction in rate of hospitalization for other reasons, although this was not statistically significant (64.2 vs 75.1 per 100 patient–years).
Sotagliflozin treatment also resulted in a significant increase in the number of days that patients spent alive and not in hospital, at 91.8 versus 88.9 years per 100 patient–years. This, however, was predominantly a result of decreased mortality in the sotagliflozin group; the time in hospital was only slightly less versus the placebo group, at 1.9 versus 2.2 years per 100 patient–years.
Szarek attributed these relatively small differences to the fact that the majority of the trial participants were not hospitalized during follow-up, and suggested that larger benefits might be seen for high-risk subgroups.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group